Monday, February 11th, 12:00pm – 12:55pm
Portfolio managers and senior buy-side analysts forecast the year ahead in biotech. This lively panel discussion will be primed with the results of this year’s Investor Perception Study, conducted by BIO’s Industry Analysis Team and ISI Group. Panelists will field a range of questions from valuations and volatility to challenges and opportunities facing institutional investors today.
- Mark Schoenebaum, MD, Senior Managing Director and Head, Healthcare Research, ISI Group
- Samuel D. Isaly, Managing Partner, OrbiMed Advisors
- Oleg Nodelman, Founder & Managing Director, EcoR1 Capital
- Nathan Sadeghi-Nejad, Partner, Palkon Capital Management
Samuel D. Isaly
Samuel D. Isaly is the Managing Partner of OrbiMed Advisors. Mr. Isaly is one of the world's most recognized healthcare fund managers and has been active in global healthcare investing and analysis since 1968 when he joined Chase Manhattan Bank in New York. During his career, Mr. Isaly has been a pharmaceutical analyst with Chase Manhattan Bank, Merrill Lynch, Legg Mason, and S.G. Warburg. Mr. Isaly launched OrbiMed's asset management business in 1989. Mr. Isaly has a B.A. in Economics from Princeton University and a M. Sc. (Econ.) from The London School of Economics.
Oleg Nodelman is the Founder and Managing Director of EcoR1 Capital, a San Francisco-based, value-oriented healthcare investment fund. EcoR1 capitalizes on opportunities in the biotechnology sector and mitigates risk through a highly engaged investment process, emphasizing the value of identifying and recruiting premier human capital in all aspects of corporate management and scientific leadership. Prior to EcoR1, Mr. Nodelman was a portfolio manager at BVF Partners L.P., the oldest dedicated biotechnology hedge fund. At BVF, Mr. Nodelman’s responsibilities included all aspects of the business including opportunity generation, deep diligence, portfolio management and trading.
Prior to joining BVF in 2001, Mr. Nodelman was a consultant with Mercer Management Consulting (now Oliver Wyman), a consulting firm focused on strategy, operations, risk management, organizational transformation and leadership development. At Mercer, he worked with senior management from companies in a variety of industries to develop and implement long-term strategy and build shareholder value. Mr. Nodelman holds a Bachelor of Science in Foreign Service with a concentration in Science and Technology from Georgetown University.
Nathan Sadeghi-Nejad received a B.A. in Philosophy with a focus on Premedical Sciences from Columbia University in 1997. Upon graduation, he joined New York-based Sturza's Research, a healthcare-focused investment research boutique and advisor to hedge funds and mutual funds. As Senior Analyst, he had responsibility for conducting and publishing research for institutional clients, as well as for making investment recommendations to Ursus Capital, the firm's hedge fund. In mid-2000, Mr. Sadeghi-Nejad joined the Florida-based independent research boutique Avalon Research as Partner and Managing Director. At Avalon, Mr. Sadeghi-Nejad led the healthcare research division, which accounted for roughly 40% of the firm's revenues. Following the sale of Avalon to BCA Research in mid-2005, Mr. Sadeghi-Nejad joined Kilkenny Capital, a $300 million Chicago-based hedge fund, as a Senior Analyst. In early 2007, Mr. Sadeghi-Nejad assumed the role of Director and healthcare sector head for Highside Capital, a $1.7 billion Dallas-based hedge fund founded by Maverick Capital veteran Lee Hobson. During his tenure at Highside, the compound return for the firm's roughly $300 million healthcare investment portfolio exceeded both the S&P Health and MS World Health indices. Mr. Sadeghi-Nejad has experience in all healthcare sub-sectors, although he has focused more extensively on therapeutics and products companies. Mr. Sadeghi-Nejad has written extensively for TheStreet and is a Contributor to Forbes. Mr. Sadeghi-Nejad joined Palkon Capital in January 2013.
Mark Schoenebaum, MD
ISI’s Health Care Research Team, headed by Mark Schoenebaum, focuses on providing actionable investment ideas and proprietary research on Biotechnology, Pharmaceutical, and Specialty Pharmaceutical stocks.